BRIEF published on 06/13/2025 at 07:35, 1 year 3 months ago MaaT Pharma Reveals Promising Data for Xervyteg® at EHA Congress Clinical Efficacy Safety Profile Xervyteg® AGvHD EMA Application
PRESS RELEASE published on 06/13/2025 at 07:30, 1 year 3 months ago Inside Information / Other news releases MaaT Pharma presents updated positive data for Xervyteg® in treating acute Graft-versus-Host Disease at EHA Congress, validating high efficacy observed in pivotal ARES study MaaT Pharma Acute Graft-versus-Host Disease EMA Approval Xervyteg EAP Data
BRIEF published on 05/12/2025 at 07:35, 1 year 4 months ago Promising data for MaaT033 in ALS Microbiome Amyotrophic Lateral Sclerosis MaaT033 Safety And Tolerability Phase 1b Clinical Trial
BRIEF published on 04/08/2025 at 07:35, 1 year 5 months ago MaaT Pharma Announces Positive Interim Safety Results for MaaT033 Phase 2B Trial MaaT Pharma MaaT033 Allo-HSCT DSM Safety
PRESS RELEASE published on 04/08/2025 at 07:30, 1 year 5 months ago Inside Information / Other news releases MaaT Pharma announces positive safety interim analysis from DSMB for Phase 2b trial evaluating MaaT033 for patients receiving Allo-HSCT, demonstrating favorable safety profile and tolerability Phase 2B Trial MaaT Pharma Safety Analysis MaaT033 Allo-HSCT
BRIEF published on 04/07/2025 at 07:35, 1 year 5 months ago MaaT Pharma: New cover by HC Wainwright & Co Cancer Euronext Listing Microbiome Ecosystem Therapies MaaT Pharma HC Wainwright & Co
BRIEF published on 03/27/2025 at 07:35, 1 year 5 months ago MaaT Pharma announces a capital increase of 13 million euros and 2024 annual results Financial Results Biotechnology Capital Increase MaaT013 AGvH
BRIEF published on 01/21/2025 at 18:05, 1 year 7 months ago Positive Results for MaaT033 Clinical Trial Biotechnology Security Oncology Clinical Trial MaaT033
PRESS RELEASE published on 12/10/2024 at 02:30, 1 year 9 months ago Inside Information / Other news releases
BRIEF published on 10/15/2024 at 07:35, 1 year 11 months ago MaaT Pharma Clinical Trial Recruitment Concluded Clinical Trial MaaT Pharma MaaT013 DSMB Notice AGvH Treatment
Published on 09/19/2026 at 00:55, 22 hours 10 minutes ago Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 23:50, 23 hours 15 minutes ago Mako Mining Announces Equity Incentive Grants
Published on 09/18/2026 at 22:00, 1 day 1 hour ago Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 1 day 2 hours ago Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 1 day 8 hours ago AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/19/2026 at 16:40, 6 hours 24 minutes ago 2026 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival Opens
Published on 09/19/2026 at 13:15, 9 hours 50 minutes ago Eurobattery Minerals AB has received information regarding court judgment and criminal suspicion concerning the CEO
Published on 09/19/2026 at 07:30, 15 hours 35 minutes ago Hong Kong sets out initiatives to secure long-term development of pillar industries
Published on 09/18/2026 at 18:44, 1 day 4 hours ago EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:34, 1 day 4 hours ago Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/17/2026 at 17:40, 2 days 5 hours ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
